⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Osaka Synthetic Chemical Laboratories, Inc. (株式会社大阪合成有機化学研究所) and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Osaka Synthetic Chemical Laboratories, Inc. (株式会社大阪合成有機化学研究所)
↗Nishinomiya, Hyogo, Japan
Osaka Synthetic Chemical Laboratories, Inc. (OSCL/OSC) is a Japanese pharmaceutical-chemicals manufacturer founded in 1961. Its core businesses are the manufacture and sale of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, contract-manufactured APIs including clinical-trial material, and industrial/synthetic chemistry reagents. The company’s portfolio includes generic-drug APIs, peptide-synthesis reagents, DCC/EDC-related products, and AmNA® amidite monomers. ([tec-osc.co.jp](https://www.tec-osc.co.jp/company/outline/))
The company operates as a wholly owned Kaneka group subsidiary and is positioned within Kaneka’s pharmaceutical and supplemental-nutrition solutions network. Its capabilities include organic synthesis, high-potency API development, process validation, GMP manufacturing, analytical development, scale-up, and continuous-flow chemistry. OSCL is a supplier/CDMO rather than a conventional drug-discovery biotech: its publicly disclosed “pipeline” is primarily a commercial API and intermediate portfolio, not proprietary clinical drug candidates. ([job.mynavi.jp](https://job.mynavi.jp/27/pc/search/corp223791/outline.html?utm_source=openai))
CLASSIFICATION
Company Type:CDMO
Therapeutic Areas:
Industry:CDMO
Sub-Industry:Small-molecule API, pharmaceutical-intermediate, and synthetic-reagent manufacturing
SIZE & FINANCIALS
Employees:201-500
Revenue:$50M-$100M; reported FY2025 revenue was approximately ¥7.798B. Public sources vary on employee count and revenue by reporting date, with other estimates ranging from approximately 220 to 327 employees and ¥6.2B-¥7.0B in revenue. ([job.mynavi.jp](https://job.mynavi.jp/27/pc/search/corp223791/outline.html))
Founded:1961
Ownership:subsidiary
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial API portfolio; no proprietary clinical-stage drug candidate publicly identified
Modalities:Small molecules, Generic APIs, Pharmaceutical intermediates, High-potency APIs, Peptide-synthesis reagents, AmNA® amidite monomers, Continuous-flow chemistry, Chiral compounds
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Kaneka Corporation
Key Partnerships:Kaneka Corporation: 100% parent and strategic manufacturing/process-development partner. OSCL became a Kaneka group company in 2002; the companies collaborate on API technology, continuous-flow chemistry, process development, and commercial manufacturing. ([tec-osc.co.jp](https://www.tec-osc.co.jp/company/outline/)), Zhejiang Ausun Pharmaceutical Co., Ltd.: identified on OSCL’s API portfolio as the manufacturer associated with several process-validation products, including ramelteon, tafluprost, miglitol, and sugammadex sodium; the precise commercial relationship is not publicly detailed. ([tec-osc.co.jp](https://www.tec-osc.co.jp/business/genyaku/))
COMPETITION
Position:Niche Player; assessment is an inference based on OSCL’s specialized Japanese API/CDMO footprint, Kaneka ownership, commercial generic-API portfolio, and continuous-flow/high-potency capabilities. ([fcd.kaneka.co.jp](https://www.fcd.kaneka.co.jp/en/about/?utm_source=openai))
Competitors:Kyowa Pharma Chemical Co., Ltd., API Corporation, Nippon Fine Chemical Co., Ltd., Sanyo Fine Co., Ltd., Kongo Chemical Co., Ltd., Fuji Chemical Industries Co., Ltd., Nipro Pharma Corporation, Lonza Group +2 more
LEADERSHIP
Key Executives:
Zenichi Kogame - Representative Director and President
LINKS
Website:tec-osc.co.jp
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Osaka Synthetic Chemical Laboratories, Inc. (株式会社大阪合成有機化学研究所). The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.